Quicksome™: A Step Forward in Needle-Free Hormone Delivery

This morning we announced results from our exploratory human Quicksome™ testosterone study, and I am pleased to share why I believe this work represents an important step for the Company. For those who have not yet seen the announcement, the full release is available HERE.

In recent updates, I have spoken about the evolution of Quicksome from individual product applications toward a broader formulation and delivery platform. A central part of that vision is to create practical needle-free options for selected hormones and peptides currently administered by injection. Today’s announcement adds meaningful human data to that progression and gives our team a clearer foundation for the hormone formulations we are advancing.

A few highlights from the study:

• Eight participants, ranging in age from 28 to 71. Six received a 15 mg Quicksome testosterone tablet, and two received a 5 mg tablet. Participant-facing procedures were conducted by third-party medical personnel under medical oversight.
• Substantial increases in blood testosterone concentrations were observed in all eight participants. The increases occurred rapidly following administration.
• Observed peak concentrations occurred approximately 10 to 30 minutes after dosing. Six of the eight participants reached their observed peak at approximately 20 minutes.
• The 15 mg formulation produced substantial increases across six participants. Their individual average pre-dose testosterone concentrations ranged from approximately 311 to 432 ng/dL, while their individual observed peak concentrations ranged from 1,436 to 5,981 ng/dL.
• The lower 5 mg formulation also produced substantial increases in both participants. One participant’s serum testosterone rose from an average pre-dose baseline of approximately 626 ng/dL to an observed peak of 5,263 ng/dL. The other participant’s concentration rose from approximately 272 ng/dL to an observed peak of 3,616 ng/dL.
• Concentrations declined following the early peak. By approximately three hours, most participants’ concentrations had returned toward their individual pre-dose levels, with the six-hour measurements generally remaining near baseline.

What was particularly encouraging to me was the amount of useful information this work generated. We were able to observe not simply whether blood concentrations increased, but how quickly they rose, when they peaked and how they subsequently declined. Together with the observations on tablet dissolution, this gives our team practical information to guide the next formulation decisions.

This was a small exploratory study with a clear purpose: to understand how the formulation behaves in people and guide the next stage of development. The findings give us encouraging human data to build on, with further work needed to assess clinical benefit, optimal dosing, absolute bioavailability and comparative performance. The full release sets out the study’s scope and limitations.

The value is in what these findings allow us to build next.

For someone who relies on regular injections, the possibility of a clinically supported alternative that dissolves under the tongue is a tangible opportunity. That is what makes this direction important to me. We are working toward formulations that could change the day-to-day experience of administering important medicines, not simply generate another laboratory result.

Our hormone work has a defined direction. Alongside testosterone, current formulation development includes estradiol and progesterone. Each molecule requires its own evaluation, but the testosterone findings can inform how we approach formulation design, dose loading, dissolution and future testing across that program. The same principle applies to our broader peptide work: the opportunity is significant, but performance must be established molecule by molecule.

This also connects with the compounding-pharmacy work I have discussed in previous shareholder updates. We have been developing Quicksome with potential commercial applications and the capabilities of appropriate partners in mind. Our work with compounding, manufacturing and commercialization partners forms part of the broader pathway we have outlined across hormones, peptides and other human-health applications.

That is why I view today’s announcement as more than an isolated research result. Understanding how a formulation behaves in people helps us make better decisions about the products we seek to advance and the evidence needed to support them. Further development and applicable regulatory requirements remain part of that process.

I am proud of the work led by Richa Mandalay and our research team, and grateful to Sanjeev Goel, MD and the medical personnel who supported the study. There is considerable detail behind a dataset like this, and that work now gives us a more informed starting point for the next stage.

When we introduced The More Life Company, I spoke about the importance of measurable performance, commercial relevance and the ability to scale. Those remain the standards guiding how we develop our technologies and assess the opportunities in front of us.

Today’s results represent another step in that direction. We have additional human data, a defined hormone-development program and a clearer understanding of the formulation work needed to move forward. I am encouraged by the opportunity to build on that foundation, working toward practical needle-free options for selected hormone and peptide applications and translating that progress into long-term shareholder value.

Thank you for your continued support and belief in our vision of More Life.

Sincerely,

Dennis Hancock

President & CEO @ The More Life Company